Rx License-Rx

R3651-tpNCD

TNF-R1 Selective Allosteric Inhibitors

Tumor Necrosis Factor (TNF) is a potent pro-inflammatory cytokine whose dysregulation has been found to cause rheumatoid arthritis, stroke and a broad range of inflammatory disease. Inhibition of TNF receptors has become an effective means to ameliorate inflammatory disease, however, pan TNF-R antagonists increase risk of infection and malignancy. Using a novel structure based design approach to identify small molecule compounds that bind to an allosteric site on TNF-R1, thus inhibiting binding of TNF-alpha to TNF-R1 and reducing activation of the TNF-alpha/TNF-R1 signaling pathway, the inventors have uncovered a new class of compounds that are effective at inhibiting the pathologic side-effects of TNF signaling while preserving the patient's ability to mount an immune response against pathogens. Lead candidates are potent, highly specific and have been demonstrated to ameliorate arthritis in vivo. Inventors: Mark Greene.

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Inflammatory disease

Modality: Small Molecule

Focus tags: Oncology, Immunology, Inflammation, Infectious Disease

Technology tags: Small Molecule

Mechanism:

Development stage: Preclinical

Patent status: US 8,765,810 US 9,096,607 US 8,318,699 EPO 1845970 EPO 2305246 EPO 2298295 Canada 2596355 Australia 2006210778

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Inflammatory disease. Public description: Tumor Necrosis Factor (TNF) is a potent pro-inflammatory cytokine whose dysregulation has been found to cause rheumatoid arthritis, stroke and a broad range of inflammatory disease. Inhibition of TNF receptors has become an effective means.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Inflammatory disease

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.